Acne
Conditions
Interventions
Group A:Received a fixed daily dose of 20 mg isotretinoin, which resulted in an actual dose range of 0.18 to 0.36 mg/kg/day based on their weight between 55 and 110 kg. The patients also received frac
Group B:Received standard weight-based isotretinoin at 0.5 mg/kg/day
Sponsors
University of Mosul
Eligibility
Sex/Gender
All
Age
18 Years to 33 Years
Inclusion criteria
Inclusion criteria: The study included patients aged 18 to 33 years with moderate-to-severe acne vulgaris of the face, as defined by an Investigator Global Assessment (IGA) score of 3 or 4. All patients had failed or were unsuitable for conventional topical therapy alone.
Exclusion criteria
Exclusion criteria: Patients were excluded from the study when they met any of these criteria: 1.They had used isotretinoin during the last 12 months; 2.They had documented hypersensitivity to retinoids; 3.They were currently suffering from active hepatic or renal or metabolic diseases; 4.Females were pregnant or they refused to follow birth control rules; 5.They had an existing skin infection at the sites where RF treatment was scheduled; 6.They had received RF microneedling treatment within the 6 months before their enrollment date.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Investigator's Global Assessment (IGA) score from baseline to week 16, on a validated 5-point scale (0 = clear, 4 = severe); | — |
Secondary
| Measure | Time frame |
|---|---|
| counting inflammatory lesions at week 8 and at the end of the trial (EOT); ;Assessing treatment failure rate at 6 months, which occurred when IGA score remained above 2;Evaluating safety and tolerability through the documented adverse events.;Change in Patient Satisfaction Score (PSS) on a 10-point Likert scale at week 8; | — |
Countries
Iraq
Contacts
Public ContactAhmed M. Al Obaidi
University of Mosul
Outcome results
None listed